Merrill Joan T, Asherson Ronald A
University of Oklahoma, USA.
Nat Clin Pract Rheumatol. 2006 Feb;2(2):81-9. doi: 10.1038/ncprheum0069.
Antiphospholipid syndrome (APS) is a thrombotic disorder associated with autoantibodies that target membrane phospholipids and phospholipid-binding proteins, which regulate coagulation. APS is usually characterized by major arterial or venous occlusions, pregnancy complications, or both. In 1992, Asherson described an unusual variant of APS termed the catastrophic antiphospholipid syndrome (also known as Asherson's syndrome), the hallmark of which is rapid multiorgan failure caused by widespread small-vessel thrombi. Empiric treatments have improved the prognosis of patients, but half still die from thrombotic diathesis, even though those who survive the acute stages frequently remain well. Given the persistently high mortality rate, efforts have been underway to facilitate early diagnosis, institute effective treatments in a timely manner and to better understand the cause (or causes) of this extreme condition in order to improve outcomes.
抗磷脂综合征(APS)是一种与自身抗体相关的血栓形成性疾病,这些自身抗体靶向膜磷脂和调节凝血的磷脂结合蛋白。APS通常以主要的动脉或静脉闭塞、妊娠并发症或两者兼有为特征。1992年,阿舍尔森描述了一种不寻常的APS变体,称为灾难性抗磷脂综合征(也称为阿舍尔森综合征),其标志是由广泛的小血管血栓形成导致的快速多器官衰竭。经验性治疗改善了患者的预后,但仍有一半患者死于血栓形成素质,尽管那些在急性期存活下来的患者通常情况良好。鉴于死亡率持续居高不下,人们一直在努力促进早期诊断、及时实施有效治疗,并更好地了解这种极端情况的病因,以改善治疗结果。